AIM ImmunoTech’s shareholder meeting adjourned when proxies covered about 32.5% of voting shares.

Nov 18, 2026
aim-immunotech’s-shareholder-meeting-adjourned-when-proxies-covered-about-325%-of-voting-shares.

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Lack of a quorum delayed the annual meeting from November 17 to December 8, 2026.”]” data-initial-positive=”[]” data-news-id=”1535918″ data-rhea-loading=”false” data-ui-labels=”{“en”:{“summary”:”Rhea-AI Summary”,”positive”:”Positive”,”negative”:”Negative”,”insights”:”Insights”,”tags”:”Tags”,”none”:”None.”},”ko”:{“summary”:”Rhea-AI 요약”,”positive”:”긍정적”,”negative”:”부정적”,”insights”:”인사이트”,”tags”:”태그”,”none”:”없음.”},”it”:{“summary”:”Riepilogo Rhea-AI”,”positive”:”Positivo”,”negative”:”Negativo”,”insights”:”Approfondimenti”,”tags”:”Tag”,”none”:”Nessuno.”},”es”:{“summary”:”Resumen Rhea-AI”,”positive”:”Positivo”,”negative”:”Negativo”,”insights”:”Perspectivas”,”tags”:”Etiquetas”,”none”:”Ninguno.”},”de”:{“summary”:”Rhea-AI Zusammenfassung”,”positive”:”Positiv”,”negative”:”Negativ”,”insights”:”Einblicke”,”tags”:”Tags”,”none”:”Keine.”},”fr”:{“summary”:”Résumé Rhea-AI”,”positive”:”Positif”,”negative”:”Négatif”,”insights”:”Perspectives”,”tags”:”Tags”,”none”:”Aucun.”},”ar”:{“summary”:”ملخص Rhea-AI”,”positive”:”إيجابي”,”negative”:”سلبي”,”insights”:”رؤى”,”tags”:”العلامات”,”none”:”لا شيء.”}}” data-user-preferred-lang=”en” id=”rhea-summary-container”>

Rhea-AI Summary

AIM ImmunoTech (AIM) adjourned its 2026 annual shareholder meeting for lack of a quorum and will reconvene it on December 8, 2026.

When the November 17 meeting adjourned, submitted proxies represented approximately 32.5% of outstanding shares entitled to vote. The quorum threshold was 33 and 1/3% of outstanding common shares entitled to vote, present or represented by proxy. The meeting will resume virtually at 11:00 a.m. Eastern Time. The proposals are unchanged, and the voting record date remains the close of business on September 28, 2026.

Loading…

Loading translation…

Negative

  • Minor pointLack of a quorum delayed the annual meeting from November 17 to December 8, 2026.

At the annual meeting’s December 8, 2026 reconvening, stockholders who previously submitted a proxy or otherwise voted and do not want to change their vote need take no further action.

Quorum threshold
33 and 1/3% of common stock outstanding and entitled to vote
Shares present or represented by proxy required at the annual meeting

Shares represented by proxy
approximately 32.5%
At adjournment; below the stated quorum threshold

Reconvened meeting
December 8, 2026 at 11:00 A.M. Eastern Time
Adjourned 2026 Annual Meeting

quorum regulatory

“did not have a sufficient number of shares … to constitute a quorum”

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

definitive proxy statement regulatory

“the Company’s definitive proxy statement for the Annual Meeting”

A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what’s being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

OCALA, Fla., Nov. 18, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), originally scheduled for and convened on November 17, 2026, has been adjourned until December 8, 2026 at 11:00 A.M. Eastern Time, because the Company did not have a sufficient number of shares of the Company’s common stock present or represented by proxy at the Annual Meeting to constitute a quorum and to provide stockholders additional time to review the proxy materials and vote on the proposals described in the Company’s definitive proxy statement for the Annual Meeting filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 30, 2026 (the “Annual Meeting Proxy Statement”).

A quorum would have been present if shares representing 33 and 1/3% of the common stock outstanding and entitled to vote were present at the Annual Meeting or represented by proxy. At the time the Annual Meeting was adjourned, proxies had been submitted by stockholders representing approximately 32.5% of the outstanding shares of stock entitled to vote, so a quorum did not exist.

The Annual Meeting will be reconvened on December 8, 2026 at 11:00 A.M. Eastern Time and will continue to be held in a virtual format. Stockholders will be able to virtually attend the Annual Meeting by visiting https://web.viewproxy.com/AIM/2026.

The record date for the determination of stockholders of the Company entitled to vote at the adjourned Annual Meeting remains the close of business on September 28, 2026. No changes have been made to the proposals to be voted on by the stockholders at the Annual Meeting. Stockholders who have previously submitted their proxy or otherwise voted and do not want to change their vote do not need to take any action.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any forward-looking statements set forth in this press release speak only as of the date hereof. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Such forward-looking statements may include statements relating to the timing of the Annual Meeting and related matters. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company does not undertake to update any forward-looking statements except as required by applicable law.

For a discussion of risk factors, please see the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only.





Investor Contact:  JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Leave a comment